Treatment of Cervical Spinal Cord Injury With Imatinib - a Safety and Feasibility Study
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II, single center, open-label, non randomized clinical study to assess the
uptake, safety and tolerability of Imatinib in acute Cervical Spinal Cord Injury patients.
The aim is to determine if Imatinib reaches sufficient blood levels when given to patients
with cervical spinal cord injury, via a gastric feeding tube, and also evaluate the safety
and tolerability of this drug treatment.